New Novartis ESC data highlights strength of cardiovascular portfolio
Novartis News Novartis ianalumab Phase III trial meets primary endpoint in ITP, demonstrating statistically significant improvement in time to treatment failure
Novartis ianalumab Phase III trial meets primary endpoint in ITP, demonstrating statistically significant improvement in time to treatment failure
arcticnovartis
Novartis News Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren’s disease
Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren’s disease
arcticnovartis
Ad hoc announcement pursuant to Art. 53 LR
Follow us on Facebook
ADDRESS – ZIMBABWE
Suite 204, Block 1
Long Cheng Plaza
Mutley Bend, Belvedere
Harare, Zimbabwe
ADDRESS – ZAMBIA
Plot 43504
Apex Chalala
Off Kasama Road
Lusaka Zambia